This currently ongoing research study investigates the association between anti-TB drug concentrations and TB treatment outcome in TB/HIV co-infected Ugandan adults. Serum concentrations of all four standard anti-TB drugs, as well as selected antiretroviral drugs are measured at baseline, week 2, week 8, and week 24 of anti-TB treatment. Additionally, data on symptoms, sputum smear and culture, as well as radiological features is collected. Serum drug concentrations are measured on site by a Ugandan laboratory technician trained in Zurich using a validated UV-HPLC method. Furthermore, the SOUTH study serves as a research platform for a variety of nested studies.
- HIV virological failure screening & HIV resistance testing
- Efavirenz serum concentrations measurement
- Diabetes Screening